Unnamed: 0 int64 0 350k | level_0 int64 0 351k | ApplicationNumber int64 9.75M 96.1M | ArtUnit int64 1.6k 3.99k | Abstract stringlengths 1 8.37k | Claims stringlengths 3 292k | abstract-claims stringlengths 68 293k | TechCenter int64 1.6k 3.9k |
|---|---|---|---|---|---|---|---|
1,000 | 1,000 | 15,632,662 | 1,612 | The invention relates to a lubricating member for a razor cartridge comprising a metathesized unsaturated polyol ester for improved lubrication. | 1. A lubricating member for use on a hair removal device, said lubricating member comprising a lubricating material comprising a) from 1% to 99% by weight of methathesized unsaturated polyol ester methathesized unsaturated polyol ester, having one or more of the following properties:
(i) a weight average molecular weig... | The invention relates to a lubricating member for a razor cartridge comprising a metathesized unsaturated polyol ester for improved lubrication.1. A lubricating member for use on a hair removal device, said lubricating member comprising a lubricating material comprising a) from 1% to 99% by weight of methathesized unsa... | 1,600 |
1,001 | 1,001 | 15,198,234 | 1,612 | A consumer product including a fabric and home composition providing for multiple blooms of fragrance, the multiple blooms being provided for by different populations of microcapsules and method related thereto. | 1. A consumer product comprising a composition, the composition comprising:
an adjunct material; a first population of microcapsules, the first population having a first median volume weighted particle size and comprising microcapsules comprising a partitioning modifier and a first perfume oil at a first weight ratio; ... | A consumer product including a fabric and home composition providing for multiple blooms of fragrance, the multiple blooms being provided for by different populations of microcapsules and method related thereto.1. A consumer product comprising a composition, the composition comprising:
an adjunct material; a first popu... | 1,600 |
1,002 | 1,002 | 15,100,990 | 1,612 | A composition comprising a zinc ion source for use in inhibiting the adherence to or invasion of oral soft tissue, such as gingival epithelial cells, by a periodontal pathogen is provided. | 1. A composition comprising a zinc ion source for use in inhibiting the adherence to or invasion of oral soft tissue epithelial cells by a periodontal pathogen. 2. The composition of claim 1, wherein the oral soft tissue is gingival epithelial cells. 3. The composition of claim 1, wherein the periodontal pathogen cause... | A composition comprising a zinc ion source for use in inhibiting the adherence to or invasion of oral soft tissue, such as gingival epithelial cells, by a periodontal pathogen is provided.1. A composition comprising a zinc ion source for use in inhibiting the adherence to or invasion of oral soft tissue epithelial cell... | 1,600 |
1,003 | 1,003 | 13,814,009 | 1,653 | Methods, devices, and systems are provided for guiding tumor movement, particularly in vivo for treatment of patients. The method may include implanting into a tissue site where tumor cells are present a device having one or more surface structures or substrates, such as aligned nanofibers, which provide physical guida... | 1. An implantable system for promoting tumor cell migration for cell removal or death, the system comprising:
at least one substrate having a surface configured to provide cues for directing tumor cell migration along the substrate surface, the at least one substrate comprising a plurality of aligned nanofibers; and at... | Methods, devices, and systems are provided for guiding tumor movement, particularly in vivo for treatment of patients. The method may include implanting into a tissue site where tumor cells are present a device having one or more surface structures or substrates, such as aligned nanofibers, which provide physical guida... | 1,600 |
1,004 | 1,004 | 14,786,980 | 1,623 | Phosphorylated hydrogels obtained by co-cross-linking hyaluronic acid with dextran, a process for preparing same, and a use of the hydrogel for the encapsulation and extended release of active principles as well as cells for use in regenerative human and veterinary medicine. | 1-12. (canceled) 13. A co-cross-linked phosphorylated polysaccharide hydrogel, comprising:
dextran; and hyaluronic acid and/or one of its salts, optionally functionalized, wherein said dextran and said hyaluronic acid and/or its salt, optionally functionalized, are bound together by phosphodiester and/or polyphosphodie... | Phosphorylated hydrogels obtained by co-cross-linking hyaluronic acid with dextran, a process for preparing same, and a use of the hydrogel for the encapsulation and extended release of active principles as well as cells for use in regenerative human and veterinary medicine.1-12. (canceled) 13. A co-cross-linked phosph... | 1,600 |
1,005 | 1,005 | 14,770,862 | 1,628 | Compositions comprising 2-((5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenyloxy)butanoic acid, an ester derivative, or a pharmaceutically acceptable salt thereof; a triglyceride; and a surfactant, as well as methods for their use. The present disclosure further relates to self-emulsifying drug delivery systems, such as ... | 1-138. (canceled) 139. A composition comprising
from 5% to 60% by weight of the total composition of 2-((5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenyloxy)butanoic acid, an ester derivative, or a pharmaceutically acceptable salt thereof; from 15% to 60% by weight of the total composition of a medium-chain triglyceride... | Compositions comprising 2-((5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenyloxy)butanoic acid, an ester derivative, or a pharmaceutically acceptable salt thereof; a triglyceride; and a surfactant, as well as methods for their use. The present disclosure further relates to self-emulsifying drug delivery systems, such as ... | 1,600 |
1,006 | 1,006 | 16,027,997 | 1,617 | A synergistic agricultural formula including at least one diacyl or diaryl urea, such as a N,N′-diformylurea, and at least one plant growth regulator. This synergistic agricultural formula gives those skilled in the art the ability to regulate important phenotypical parameters that lead to a variety of important agrono... | 1. An agricultural formula comprising 30 to 0.1% of at least one diacyl or diaryl urea and 0.001 to 99.9 wt % of at least one plant growth regulator. 2. The agricultural formula of claim 1, wherein said at least one diacyl or diaryl urea is only at least one diacyl urea. 3. The agricultural formula of claim 1, wherein ... | A synergistic agricultural formula including at least one diacyl or diaryl urea, such as a N,N′-diformylurea, and at least one plant growth regulator. This synergistic agricultural formula gives those skilled in the art the ability to regulate important phenotypical parameters that lead to a variety of important agrono... | 1,600 |
1,007 | 1,007 | 16,535,704 | 1,628 | Provided herein are methods for administering dichlorphenamide, or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the subject is also being administered an organic anion transporter-1 (OAT1) substrate. The method comprises administering to the subject a therapeutically effective amoun... | 1. A method for administering dichlorphenamide, or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the subject is being administered an organic anion transporter-1 (OAT1) substrate to treat a disease or disorder, the method comprising:
discontinuing administration of the OAT1 substrate... | Provided herein are methods for administering dichlorphenamide, or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the subject is also being administered an organic anion transporter-1 (OAT1) substrate. The method comprises administering to the subject a therapeutically effective amoun... | 1,600 |
1,008 | 1,008 | 16,253,515 | 1,628 | Provided herein is a method of administering dichlorphenamide, or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the subject is also being administered an organic anion transporter-1 (OAT1) inhibitor and/or an organic anion transporter-3 (OAT3) inhibitor. The method comprises administ... | 1.-29. (canceled) 30. A method of treating a disease chosen from primary hyperkalemic periodic paralysis, primary hypokalemic periodic paralysis, and related variants in a subject in need thereof,
wherein the subject is exhibiting one or more signs of dichlorphenamide toxicity as a result of increase in exposure of dic... | Provided herein is a method of administering dichlorphenamide, or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the subject is also being administered an organic anion transporter-1 (OAT1) inhibitor and/or an organic anion transporter-3 (OAT3) inhibitor. The method comprises administ... | 1,600 |
1,009 | 1,009 | 15,954,291 | 1,632 | Methods are disclosed for reprogramming a somatic cell, including an adherent cell and a cell in suspension, into an induced pluripotent stem comprising expressing exogenous Sox-2, exogenous Klf-4, exogenous Oct3/4 from DNA that has not integrated into the genome of the somatic cell, suppressing p53 activity within the... | 1. A method for reprogramming a somatic cell into an induced pluripotent stem (iPS) cell in vitro comprising:
expressing exogenous sex determining region Y-box 2 (Sox-2), Kruppel-like factor 4 (Klf-4), and octamer-binding transcription factor 3/4 (Oct3/4) in the somatic cell from DNA that has not integrated into genomi... | Methods are disclosed for reprogramming a somatic cell, including an adherent cell and a cell in suspension, into an induced pluripotent stem comprising expressing exogenous Sox-2, exogenous Klf-4, exogenous Oct3/4 from DNA that has not integrated into the genome of the somatic cell, suppressing p53 activity within the... | 1,600 |
1,010 | 1,010 | 14,206,369 | 1,619 | Described are transdermal drug delivery compositions comprising amphetamine, methods of making them and therapeutic methods using them. The compositions are provided in a flexible, finite form (e.g. “patch”-type systems) and comprise a polymer matrix that includes amphetamine and an acrylic block copolymer. | 1. A composition for the transdermal delivery of amphetamine in the form of a flexible finite system for topical application, comprising a polymer matrix comprising amphetamine or a pharmaceutically acceptable salt or prodrug thereof, wherein the polymer matrix comprises an acrylic block copolymer. 2. The composition o... | Described are transdermal drug delivery compositions comprising amphetamine, methods of making them and therapeutic methods using them. The compositions are provided in a flexible, finite form (e.g. “patch”-type systems) and comprise a polymer matrix that includes amphetamine and an acrylic block copolymer.1. A composi... | 1,600 |
1,011 | 1,011 | 15,427,952 | 1,618 | The present invention is directed to benzazepin-1-ol-derived compounds for use in the diagnosis of NMDA receptor-associated diseases or disorders by positron emission tomography (PET). The invention also relates to a method for the diagnosis of NMDA-receptor-associated diseases or disorders by administering to a patien... | 1. A method for the diagnosis of NMDA-receptor-associated diseases or disorders comprising the following steps:
(a) administering to a patient in need of such diagnosis a radioactively labelled compound in an amount effective for PET imaging of NMDA receptors, (b) recording at least one PET scan, and (c) diagnosing the... | The present invention is directed to benzazepin-1-ol-derived compounds for use in the diagnosis of NMDA receptor-associated diseases or disorders by positron emission tomography (PET). The invention also relates to a method for the diagnosis of NMDA-receptor-associated diseases or disorders by administering to a patien... | 1,600 |
1,012 | 1,012 | 15,954,784 | 1,612 | Described herein, are compositions comprising an effective amount of a basic amino acid in free or salt form, and a water soluble strontium salt; and methods of making and using the same. | 1-11. (canceled) 12. A method to:
a. reduce or inhibit formation of dental caries, b. reduce, repair or inhibit early enamel lesions, c. reduce or inhibit demineralization and promote remineralization of the teeth, d. reduce hypersensitivity of the teeth, e. reduce or inhibit gingivitis, f. promote healing of sores or ... | Described herein, are compositions comprising an effective amount of a basic amino acid in free or salt form, and a water soluble strontium salt; and methods of making and using the same.1-11. (canceled) 12. A method to:
a. reduce or inhibit formation of dental caries, b. reduce, repair or inhibit early enamel lesions,... | 1,600 |
1,013 | 1,013 | 14,282,702 | 1,645 | This invention relates to a method of treating a dog for canine diseases comprising administering to the dog therapeutically effective amounts of a vaccine, wherein the vaccine comprises viral antigens, a bacterin, or both, and wherein the vaccine is administered subcutaneously or orally according to the schedules prov... | 1. A method of treating a dog for canine diseases comprising administering to the dog therapeutically effective amounts of vaccine, wherein the vaccine comprises viral antigens, a bacterin, or both, and wherein the vaccine is administered subcutaneously or orally in a first dose, orally in a second dose, orally in an o... | This invention relates to a method of treating a dog for canine diseases comprising administering to the dog therapeutically effective amounts of a vaccine, wherein the vaccine comprises viral antigens, a bacterin, or both, and wherein the vaccine is administered subcutaneously or orally according to the schedules prov... | 1,600 |
1,014 | 1,014 | 15,100,160 | 1,627 | Disclosed is sublingual administration of riluzole. In particular, a method for treating a neuropsychiatric disorder or symptom by administering a sublingual formulation of riluzole is provided. In addition, a method of relieving or reducing oral pain using the sublingual formulation of riluzole is disclosed. | 1. A sublingual formulation in the form of a lyophilized pharmaceutical composition that provides sublingual adsorption of riluzole comprising a pharmaceutically effective amount of riluzole or a pharmaceutically acceptable salt, solvate, anomer, enantiomer, hydrate or prodrug thereof, said formulation further comprisi... | Disclosed is sublingual administration of riluzole. In particular, a method for treating a neuropsychiatric disorder or symptom by administering a sublingual formulation of riluzole is provided. In addition, a method of relieving or reducing oral pain using the sublingual formulation of riluzole is disclosed.1. A subli... | 1,600 |
1,015 | 1,015 | 14,903,425 | 1,631 | A method of estimating transcript abundances includes: (a) obtaining transcript fragment sequencing data from a potential mixture of transcripts of a genetic locus of interest; (b) assigning this data to genetic coordinates of the locus of interest to obtain a data set of fragment genetic coordinate coverage and a cove... | 1. Method of estimating transcript abundances comprising the steps of:
a) obtaining transcript fragment sequencing data from a potential mixture of transcripts of a genetic locus of interest, b) assigning said fragment sequencing data to genetic coordinates of said locus of interest thereby obtaining a data set of frag... | A method of estimating transcript abundances includes: (a) obtaining transcript fragment sequencing data from a potential mixture of transcripts of a genetic locus of interest; (b) assigning this data to genetic coordinates of the locus of interest to obtain a data set of fragment genetic coordinate coverage and a cove... | 1,600 |
1,016 | 1,016 | 15,643,727 | 1,617 | Stable liquid formulations containing picosulfate and magnesium citrate are provided. The formulations are useful to treat constipation or for the clearance of the bowel prior to X-ray examination, endoscopy or surgery. | 1. A liquid formulation comprising:
picosulfate; magnesium citrate, and an antioxidant. 2. The liquid formulation of claim 1, wherein the picosulfate is sodium picosulfate. 3. The liquid formulation of claim 1, wherein the picosulfate is present in the formulation at a concentration in the range from about 0.10 mM to a... | Stable liquid formulations containing picosulfate and magnesium citrate are provided. The formulations are useful to treat constipation or for the clearance of the bowel prior to X-ray examination, endoscopy or surgery.1. A liquid formulation comprising:
picosulfate; magnesium citrate, and an antioxidant. 2. The liquid... | 1,600 |
1,017 | 1,017 | 15,096,318 | 1,613 | A multi-part kit system comprising (i) a solid part A which comprises 10 to 80 wt. % of peroxy compound selected from the group consisting of KHSO 5 , K 2 S 2 O 8 , Na 2 S 2 O 8 , magnesium monoperoxyphthalate hexahydrate, sodium percarbonate and sodium perborate, 0.1 to 10 wt. % of LiCl, NaCl and/or KCl and 1 to 20 wt... | 1. A multi-part kit system comprising:
(i) a solid part A which comprises 10 to 80 wt. % of at least one peroxy compound selected from the group consisting of KHSO5, K2S2O8, Na2S2O8, magnesium monoperoxyphthalate hexahydrate, sodium percarbonate, and sodium perborate; 0.1 to 10 wt. % of at least one MCI compound wherei... | A multi-part kit system comprising (i) a solid part A which comprises 10 to 80 wt. % of peroxy compound selected from the group consisting of KHSO 5 , K 2 S 2 O 8 , Na 2 S 2 O 8 , magnesium monoperoxyphthalate hexahydrate, sodium percarbonate and sodium perborate, 0.1 to 10 wt. % of LiCl, NaCl and/or KCl and 1 to 20 wt... | 1,600 |
1,018 | 1,018 | 14,421,072 | 1,612 | Novel hydroxyalkyl methyl cellulose acetate succinates which a) have from 4.0 to less than 10.0 weight percent of succinoyl groups, b) have a weight average molecular weight M w of from 80,000 Dalton to 350,000 Dalton, and c) exhibit a turbidity of up to 41 NTU as a 1.5 weight percent solution in acetone; and novel hy... | 1. A hydroxyalkyl methyl cellulose acetate succinate
a) having from 4.0 to less than 10.0 weight percent of succinoyl groups, b) having a weight average molecular weight Mw of from 80,000 Dalton to 350,000 Dalton, measured by SEC-MALLS using as mobile phase a mixture of 40 parts by volume of acetonitrile and 60 parts b... | Novel hydroxyalkyl methyl cellulose acetate succinates which a) have from 4.0 to less than 10.0 weight percent of succinoyl groups, b) have a weight average molecular weight M w of from 80,000 Dalton to 350,000 Dalton, and c) exhibit a turbidity of up to 41 NTU as a 1.5 weight percent solution in acetone; and novel hy... | 1,600 |
1,019 | 1,019 | 15,541,852 | 1,615 | This invention relates to the use of the combination of 25-hydroxyvitamin D3 (“25-OH D3”) and antioxidants/anti-inflammatories (ascorbic acid vitamin E and canthaxanthin) to make a premix or feed which can ameliorate various problems observed in poultry which have been subject to overfeeding. Feeds containing the 25-OH... | 1. A basal poultry feed additive composition comprising a combination of 25-Hydroxyvitamin D (25-OH D), Vitamin C, Vitamin E and canthaxathin. 2. A combination according to claim 1 further comprising at least one bio-active ingredient selected from the group consisting of Vitamin D, Vitamin B2, Vitamin B6, Niacin, Pant... | This invention relates to the use of the combination of 25-hydroxyvitamin D3 (“25-OH D3”) and antioxidants/anti-inflammatories (ascorbic acid vitamin E and canthaxanthin) to make a premix or feed which can ameliorate various problems observed in poultry which have been subject to overfeeding. Feeds containing the 25-OH... | 1,600 |
1,020 | 1,020 | 15,545,005 | 1,615 | The invention provides methods and compositions for the control and treatment of pests, insects, fungi, and nematodes in seeds, nuts, cereals, grains, plant growth media, plants, plant parts, and reproductive plant parts. One embodiment of the invention provides a composition comprising a seed, nut, cereal, or grain co... | 1. (canceled) 2. The method of claim 8, wherein the curcumin solution further comprises carboxymethyl cellulose or a polymer. 3. The method of claim 8, wherein the polar aprotic solvent is dimethyl sulfoxide (DMSO) and the polar protic solvent is water. 4. (canceled) 5. (canceled) 6. The method of claim 8, wherein the ... | The invention provides methods and compositions for the control and treatment of pests, insects, fungi, and nematodes in seeds, nuts, cereals, grains, plant growth media, plants, plant parts, and reproductive plant parts. One embodiment of the invention provides a composition comprising a seed, nut, cereal, or grain co... | 1,600 |
1,021 | 1,021 | 15,079,735 | 1,653 | Provided is a method of culturing one or more microorganisms. The method includes culturing one or more microorganisms in a medium comprising crude glycerol at a first concentration level, feeding to the media an additional amount of crude glycerol, once the first concentration of glycerol is reduced to a first thresho... | 1. A method of culturing one or more microorganisms, comprising:
(a) culturing one or more microorganisms in a medium comprising crude glycerol at a first concentration level; (b) feeding to the media an additional amount of crude glycerol, once the first concentration of glycerol is reduced to a first threshold level,... | Provided is a method of culturing one or more microorganisms. The method includes culturing one or more microorganisms in a medium comprising crude glycerol at a first concentration level, feeding to the media an additional amount of crude glycerol, once the first concentration of glycerol is reduced to a first thresho... | 1,600 |
1,022 | 1,022 | 15,521,970 | 1,633 | Disclosed are methods for coating microcarriers with a marrow stromal cell derived extracellular matrix, and maintaining and expanding mammalian mesenchymal stem cells on the marrow stromal cell derived extracellular matrix coated microcarriers in culture. | 1. A method of maintaining and expanding mammalian mesenchymal stem cells in culture in an undifferentiated state, the method comprising:
a. producing a 3D extracellular matrix coating on the surface of microcarriers comprising:
i. adding the microcarriers to a culture medium;
ii. adding mammalian bone marrow stromal c... | Disclosed are methods for coating microcarriers with a marrow stromal cell derived extracellular matrix, and maintaining and expanding mammalian mesenchymal stem cells on the marrow stromal cell derived extracellular matrix coated microcarriers in culture.1. A method of maintaining and expanding mammalian mesenchymal s... | 1,600 |
1,023 | 1,023 | 14,770,096 | 1,618 | Compositions comprising self-assembled hydrogel particles formed of short peptides which comprise one or more aromatic amino acid residue(s) in an inverted emulsion are disclosed. Such hydrogel particles which encapsulate an active agent and uses thereof in therapeutic and diagnostic applications are also disclosed. | 1. A composition comprising a plurality of physically discrete hydrogel particles, each hydrogel particle comprising a three-dimensional network made of a plurality of self-assembled peptides and an aqueous medium, wherein each peptide in the plurality of peptides comprises 2-6 amino acid residues, at least one of the ... | Compositions comprising self-assembled hydrogel particles formed of short peptides which comprise one or more aromatic amino acid residue(s) in an inverted emulsion are disclosed. Such hydrogel particles which encapsulate an active agent and uses thereof in therapeutic and diagnostic applications are also disclosed.1. ... | 1,600 |
1,024 | 1,024 | 16,201,410 | 1,628 | Provided herein are methods for administering dichlorphenamide, or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the subject is also being administered an organic anion transporter-1 (OAT1) substrate. The method comprises administering to the subject a therapeutically effective amoun... | 1. A method for administering dichlorphenamide, or a pharmaceutically acceptable salt thereof, to a subject in need of dichlorphenamide, or a pharmaceutically acceptable salt thereof to treat a first disease or disorder, wherein the subject is being administered an organic anion transporter-1 (OAT1) substrate for the t... | Provided herein are methods for administering dichlorphenamide, or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the subject is also being administered an organic anion transporter-1 (OAT1) substrate. The method comprises administering to the subject a therapeutically effective amoun... | 1,600 |
1,025 | 1,025 | 15,294,488 | 1,633 | Non-human animals, tissues, cells, and genetic material are provided that comprise a modification of an endogenous non-human heavy chain immunoglobulin sequence and that comprise an ADAM6 activity functional in a rodent (e.g., a mouse), wherein the non-human animals rearrange human immunoglobulin light chain gene segme... | 1-35. (canceled) 36. A method for making a human antigen binding protein, comprising:
culturing a host cell comprising a first nucleotide sequence including a first human light chain variable region sequence operably linked to a human heavy chain constant region sequence and a second nucleotide sequence including a sec... | Non-human animals, tissues, cells, and genetic material are provided that comprise a modification of an endogenous non-human heavy chain immunoglobulin sequence and that comprise an ADAM6 activity functional in a rodent (e.g., a mouse), wherein the non-human animals rearrange human immunoglobulin light chain gene segme... | 1,600 |
1,026 | 1,026 | 15,645,436 | 1,616 | The invention relates to a solid pharmaceutical preparation comprising levothyroxine sodium, gelatine, citric acid and a filler. The solid pharmaceutical preparation has an improved stability. | 1. Solid pharmaceutical preparation comprising levothyroxine sodium, gelatine, citric acid and a filler. 2. Solid pharmaceutical preparation according to claim 1, characterized in that it comprises liothyronine sodium. 3. Solid pharmaceutical preparation according to claim 1, characterized in that the filler is a sugar... | The invention relates to a solid pharmaceutical preparation comprising levothyroxine sodium, gelatine, citric acid and a filler. The solid pharmaceutical preparation has an improved stability.1. Solid pharmaceutical preparation comprising levothyroxine sodium, gelatine, citric acid and a filler. 2. Solid pharmaceutical... | 1,600 |
1,027 | 1,027 | 15,054,803 | 1,658 | A beverage comprising protein, plant sterol ester and/or plant stanol ester, a fruit and/or vegetable preparation, and a stabiliser. | 1. A beverage comprising:
protein in an amount of 0.5-5% by weight of the beverage; plant sterol ester and/or plant stanol ester in an amount of 0.5-7% by weight of the beverage; stabilizer in an amount of 0.1-1% by weight of the beverage; and a vegetable preparation, wherein the beverage has an effective concentration... | A beverage comprising protein, plant sterol ester and/or plant stanol ester, a fruit and/or vegetable preparation, and a stabiliser.1. A beverage comprising:
protein in an amount of 0.5-5% by weight of the beverage; plant sterol ester and/or plant stanol ester in an amount of 0.5-7% by weight of the beverage; stabilize... | 1,600 |
1,028 | 1,028 | 14,962,805 | 1,648 | The present invention provides a particle comprising a polypeptide and at least one antigen, and a composition comprising thereof. | 1. A particle comprising a virus structural polypeptide and at least one antigen, wherein said virus structural polypeptide comprises at least one first attachment site and said at least one antigen comprises at least one second attachment site, and wherein said virus structural polypeptide and said antigen are linked ... | The present invention provides a particle comprising a polypeptide and at least one antigen, and a composition comprising thereof.1. A particle comprising a virus structural polypeptide and at least one antigen, wherein said virus structural polypeptide comprises at least one first attachment site and said at least one... | 1,600 |
1,029 | 1,029 | 14,641,009 | 1,619 | Drug delivery devices and methods are provided for administering gemcitabine to a patient in need of treatment of bladder cancer by intravesically administering gemcitabine into the bladder of the patient to achieve a sustained concentration of the gemcitabine in urine in the bladder sufficient to produce a therapeutic... | 1. A method of treatment of bladder cancer in a patient, comprising:
locally administering gemcitabine into the urinary bladder of the patient to achieve a sustained concentration of the gemcitabine in urine in the bladder sufficient to produce a therapeutic concentration of the gemcitabine in the bladder tissues, wher... | Drug delivery devices and methods are provided for administering gemcitabine to a patient in need of treatment of bladder cancer by intravesically administering gemcitabine into the bladder of the patient to achieve a sustained concentration of the gemcitabine in urine in the bladder sufficient to produce a therapeutic... | 1,600 |
1,030 | 1,030 | 15,746,424 | 1,699 | The abstract particularly describes the nature of this invention and the manner in which it is to be performed:—
1. Specific process and apparatus developed
The inventor has prepared a novel process to speedily and accurately detect pathogens present in a fluid sample, identify the pathogens and it's count ... | 1-10. (canceled) 11. A process for rapidly detecting bacteria in a urine sample along with corresponding susceptibility levels to multiple antibiotics, the process comprising of the following steps:
a) collecting the urine sample in a sterile container; b) preparing a bacterial growth media aliquot, wherein the bacteri... | The abstract particularly describes the nature of this invention and the manner in which it is to be performed:—
1. Specific process and apparatus developed
The inventor has prepared a novel process to speedily and accurately detect pathogens present in a fluid sample, identify the pathogens and it's count ... | 1,600 |
1,031 | 1,031 | 12,844,440 | 1,639 | We describe apparatuses, method, reagents, and kits for conducting assays as well as process for their preparation. They are particularly well suited for conducting automated sampling, sample preparation, and analysis in a multi-well plate assay format. For example, they may be used for automated analysis of liquid sam... | 1. A kit for conducting luminescence assays in multi-well plates, the kit comprising:
(a) a multi-well assay test plate comprising a plurality of assay wells for said assay; (b) an auxiliary plate comprising a plurality of auxiliary wells, said auxiliary well comprising dry assay reagents for use in said assay with sai... | We describe apparatuses, method, reagents, and kits for conducting assays as well as process for their preparation. They are particularly well suited for conducting automated sampling, sample preparation, and analysis in a multi-well plate assay format. For example, they may be used for automated analysis of liquid sam... | 1,600 |
1,032 | 1,032 | 16,062,154 | 1,612 | The disclosure describes compositions for dental varnishes, methods of making the compositions, and methods of using the compositions, such as in the treatment and prevention of hypersensitivity in teeth. | 1. A dental varnish composition comprising:
a fluoride source; a non-aqueous solvent; ethyl cellulose in an amount effective to achieve suspension of the fluoride source; and one or more resins selected from mastic, colophonium, or a combination thereof; wherein a high shear viscosity of the dental varnish composition ... | The disclosure describes compositions for dental varnishes, methods of making the compositions, and methods of using the compositions, such as in the treatment and prevention of hypersensitivity in teeth.1. A dental varnish composition comprising:
a fluoride source; a non-aqueous solvent; ethyl cellulose in an amount e... | 1,600 |
1,033 | 1,033 | 15,061,488 | 1,619 | Pharmaceutical compositions for intraocular injection are described, the compositions consisting essentially of a therapeutically effective quantity of an anti-bacterial agent (such as moxifloxacin), a therapeutically effective quantity of an anti-inflammatory agent (such as prednisolone), at least one pharmaceutically... | 1. A method for treating an ophthalmological disease, condition or pathology in a mammalian subject in need of such treatment comprising delivering to the subject a composition comprising:
(a) a therapeutic component consisting essentially of:
(a1) a therapeutically effective quantity of an anti-bacterial agent indepen... | Pharmaceutical compositions for intraocular injection are described, the compositions consisting essentially of a therapeutically effective quantity of an anti-bacterial agent (such as moxifloxacin), a therapeutically effective quantity of an anti-inflammatory agent (such as prednisolone), at least one pharmaceutically... | 1,600 |
1,034 | 1,034 | 15,057,711 | 1,619 | Pharmaceutical ophthalmic compositions are described, the compositions consisting essentially of a therapeutically effective quantity of an anti-bacterial agent (such as moxifloxacin), a therapeutically effective quantity of an anti-inflammatory agent (such as prednisolone), at least one pharmaceutically acceptable exc... | 1. A pharmaceutical composition formulated as a suspension that consists of:
(a) a dispersed phase consisting of solid particles consisting of a therapeutically effective quantity of a corticosteroid independently selected from the group consisting of prednisone, prednisolone, methylprednisone, corticol, cortisone, flu... | Pharmaceutical ophthalmic compositions are described, the compositions consisting essentially of a therapeutically effective quantity of an anti-bacterial agent (such as moxifloxacin), a therapeutically effective quantity of an anti-inflammatory agent (such as prednisolone), at least one pharmaceutically acceptable exc... | 1,600 |
1,035 | 1,035 | 15,148,574 | 1,619 | Pharmaceutical ophthalmic compositions are described, the compositions consisting essentially of a therapeutically effective quantity of an anti-bacterial agent (such as moxifloxacin), a therapeutically effective quantity of an anti-inflammatory agent (such as prednisolone), a combination of at least two solubilizing a... | 1. A pharmaceutical composition formulated as a suspension that consists of:
(a) a dispersed phase consisting of solid particles consisting of a therapeutically effective quantity of a corticosteroid independently selected from the group consisting of prednisone, prednisolone, methylprednisone, corticol, cortisone, flu... | Pharmaceutical ophthalmic compositions are described, the compositions consisting essentially of a therapeutically effective quantity of an anti-bacterial agent (such as moxifloxacin), a therapeutically effective quantity of an anti-inflammatory agent (such as prednisolone), a combination of at least two solubilizing a... | 1,600 |
1,036 | 1,036 | 14,972,822 | 1,619 | Pharmaceutical compositions for intraocular injection are described, the compositions consisting essentially of a therapeutically effective quantity of an anti-bacterial agent (such as moxifloxacin), a therapeutically effective quantity of an anti-inflammatory agent (such as prednisolone), at least one pharmaceutically... | 1. A pharmaceutical composition, comprising:
(a) a therapeutic component consisting essentially of:
(a1) a therapeutically effective quantity of an anti-bacterial agent independently selected from the group consisting of quinolone, a fluorinated quinolone and pharmaceutically acceptable salts, hydrates, solvates or N-o... | Pharmaceutical compositions for intraocular injection are described, the compositions consisting essentially of a therapeutically effective quantity of an anti-bacterial agent (such as moxifloxacin), a therapeutically effective quantity of an anti-inflammatory agent (such as prednisolone), at least one pharmaceutically... | 1,600 |
1,037 | 1,037 | 15,301,473 | 1,613 | The present invention relates to a formulation sized for injection comprising a biodegradable polyesteramide co-polymer comprising at least a diol of bicyclic-1,4:3,6-dianhydrohexitol and analgesics for use in the treatment of arthritic disorders. More specific the invention relates to a formulation comprising injectab... | 1. A formulation comprising articles sized for injection comprising a biodegradable polyesteramide co-polymer comprising at least a diol of bicyclic-1,4:3,6-dianhydrohexitol for use in the treatment of arthritic disorders. 2. A formulation according to claim 1 wherein the polyesteramide co-polymer further comprises a d... | The present invention relates to a formulation sized for injection comprising a biodegradable polyesteramide co-polymer comprising at least a diol of bicyclic-1,4:3,6-dianhydrohexitol and analgesics for use in the treatment of arthritic disorders. More specific the invention relates to a formulation comprising injectab... | 1,600 |
1,038 | 1,038 | 15,068,083 | 1,633 | The present disclosure provides certain silk-fibroin compositions with particular characteristics and/or properties. In some embodiments, the disclosure provides low molecular weight compositions. In some embodiments, the disclosure provides silk fibroin compositions that comprise an active (e.g., a biological) agent o... | 1.-81. (canceled) 82. A composition comprising
a population of silk fibroin fragments; wherein no more than 15% of the total weight of silk fibroin fragments in the population has a molecular weight exceeding 200 kDa, and wherein at least 50% by weight of the silk fibroin fragments have a molecular weight within a rang... | The present disclosure provides certain silk-fibroin compositions with particular characteristics and/or properties. In some embodiments, the disclosure provides low molecular weight compositions. In some embodiments, the disclosure provides silk fibroin compositions that comprise an active (e.g., a biological) agent o... | 1,600 |
1,039 | 1,039 | 15,213,055 | 1,613 | This invention discloses drug-delivery compositions, methods of making prodrugs, and methods of drug delivery using a self-assembled gelator. The backbone of the gelator can contain a drug or prodrug, such as acetaminophen or salicin. Additional drugs or agents can be encapsulated in the gelator. Enzymatic or hydrolyti... | 1-166. (canceled) 167. A drug delivery gel composition comprising one or more drugs for delivery, the composition comprising
a gel comprising a plurality of self-assembling amphiphilic drug-derived gelators, the self-assembling amphiphilic drug-derived gelators comprising a headgroup conjugated via a degradable linkage... | This invention discloses drug-delivery compositions, methods of making prodrugs, and methods of drug delivery using a self-assembled gelator. The backbone of the gelator can contain a drug or prodrug, such as acetaminophen or salicin. Additional drugs or agents can be encapsulated in the gelator. Enzymatic or hydrolyti... | 1,600 |
1,040 | 1,040 | 16,128,053 | 1,627 | Disclosed herein are safer formulations of resiniferatoxin (RTX) for intrathecal, intraganglionic intraarticular and pericardial administration. More specifically, there is disclosed alcohol-free formulations of RTX comprising a solubilizing component, a monosaccharide or sugar alcohol, a saline buffer, and RTX, and ha... | 1. A non-alcoholic formulation of RTX comprising from about 10 μg/mL to about 200 μg/mL RTX solubilized in a solubilizing agent, a monosaccharide or sugar alcohol, and a buffer solution, wherein the formulation has a pH from about 6.5 to about 7.5. 2. The non-alcoholic formulation of RTX of claim 1, wherein the solubil... | Disclosed herein are safer formulations of resiniferatoxin (RTX) for intrathecal, intraganglionic intraarticular and pericardial administration. More specifically, there is disclosed alcohol-free formulations of RTX comprising a solubilizing component, a monosaccharide or sugar alcohol, a saline buffer, and RTX, and ha... | 1,600 |
1,041 | 1,041 | 15,767,116 | 1,618 | Compositions and methods for administration of local anesthetics that are delivered by a single injection and enable repeated on-demand or high influx analgesia over extended periods have been developed. Pharmaceutical compositions including an effective amount of one or more sodium channel blockers including site 1 so... | 1. A pharmaceutical composition comprising
triggerable liposomes, particles or microbubbles encapsulating at least one site I sodium channel blocker, wherein the site I sodium channel blocker is released upon exposing to a triggering agent in an amount effective to produce anesthesia. 2. The pharmaceutical composition ... | Compositions and methods for administration of local anesthetics that are delivered by a single injection and enable repeated on-demand or high influx analgesia over extended periods have been developed. Pharmaceutical compositions including an effective amount of one or more sodium channel blockers including site 1 so... | 1,600 |
1,042 | 1,042 | 15,466,187 | 1,611 | The present invention relates to a Tabletting aid with a low water content and to a process for the preparation thereof. The Tabletting aid composition is a directly compressible composition, the use of which results in improved tablet properties. | 1.-20. (canceled) 21. A directly compressible tabletting composition, comprising 50-85% by weight of anhydrous calcium hydrogenphosphate, 10-40% by weight of mannitol and 5-20% by weight of sorbitol, wherein said composition has a flow angle in the range of 29 to 33.4° and a bulk density in the range of 0.56 to 0.77 g/... | The present invention relates to a Tabletting aid with a low water content and to a process for the preparation thereof. The Tabletting aid composition is a directly compressible composition, the use of which results in improved tablet properties.1.-20. (canceled) 21. A directly compressible tabletting composition, com... | 1,600 |
1,043 | 1,043 | 15,909,314 | 1,656 | Compositions and methods relating to ApoA-1 fusion polypeptides are disclosed. The fusion polypeptides include a first polypeptide segment corresponding to an ApoA-1 polypeptide or ApoA-1 mimetic, and may also include a dimerizing domain such as, e.g., an Fc region, which is typically linked carboxyl-terminal to the fi... | 1. A fusion polypeptide comprising, from an amino-terminal position to a carboxyl-terminal position, ApoA1-L1-D, wherein:
ApoA1 is a first polypeptide segment comprising an amino acid sequence having at least 95% identity with amino acid residues 19-267 or 25-267 of SEQ ID NO:2, wherein said first polypeptide segment h... | Compositions and methods relating to ApoA-1 fusion polypeptides are disclosed. The fusion polypeptides include a first polypeptide segment corresponding to an ApoA-1 polypeptide or ApoA-1 mimetic, and may also include a dimerizing domain such as, e.g., an Fc region, which is typically linked carboxyl-terminal to the fi... | 1,600 |
1,044 | 1,044 | 12,646,839 | 1,634 | Methods for detecting and assessing the progress and prognosis of gastric cancer are presented. Primers and probes for use in the methods are also disclosed as are methods for suppressing gastric cancer and kits for implementing the methods. | 1. A method for detecting gastric cancer in a biological sample, comprising the step of:
detecting methylation of a patient sample sequence of at least 15 consecutive base pairs, within a contiguous sequence at least 95% similar to the region consisting of SEQ ID NO:1; wherein significant methylation level is indicativ... | Methods for detecting and assessing the progress and prognosis of gastric cancer are presented. Primers and probes for use in the methods are also disclosed as are methods for suppressing gastric cancer and kits for implementing the methods.1. A method for detecting gastric cancer in a biological sample, comprising the... | 1,600 |
1,045 | 1,045 | 16,133,359 | 1,612 | Some embodiments described herein provide for a multi-component compositions and methods for its pharmaceutical and cosmetic use, comprising a combination of an aliphatic anionic compound, an oxidative compound, and a buffering system. Source of fluoride ion and other carriers are optional ingredients. The aliphatic an... | 1. A multi-component composition comprising:
from about 0.01% to about 5.0% of an aliphatic anionic compound, based on a total weight of the multi-component composition; from about 0.001 to about 8.0% of an oxidative compound, based on a total weight of the multi-component composition; a buffering system, wherein pH of... | Some embodiments described herein provide for a multi-component compositions and methods for its pharmaceutical and cosmetic use, comprising a combination of an aliphatic anionic compound, an oxidative compound, and a buffering system. Source of fluoride ion and other carriers are optional ingredients. The aliphatic an... | 1,600 |
1,046 | 1,046 | 15,622,247 | 1,631 | Embodiments of the present invention are directed to a computer-implemented method for positive OTU identification. A non-limiting example of the computer-implemented method includes receiving, by a processor, a plurality of sequencing reads for a metagenome sample and, for each of the plurality of sequencing reads, a ... | 1-7. (canceled) 8. A computer program product for positive operational taxonomic unit (OTU) identification, the computer program product comprising:
a computer readable storage medium having program instructions embodied therewith, wherein the instructions are executable by a processor to cause the processor to perform... | Embodiments of the present invention are directed to a computer-implemented method for positive OTU identification. A non-limiting example of the computer-implemented method includes receiving, by a processor, a plurality of sequencing reads for a metagenome sample and, for each of the plurality of sequencing reads, a ... | 1,600 |
1,047 | 1,047 | 13,800,066 | 1,632 | A novel cell type has been generated that has both Th1 characteristics and cytolytic activity. These Th1/killer cells are CD4+ cells purified from peripheral blood and manipulated to have Th1 characteristics such as production of IFN-gamma combined with cytolytic activity similar to cytotoxic T-cells (CTL). The CTL act... | 1. A composition comprising Th1/killer cells wherein the Th1/killer cells have Th1 characteristics and cytolytic activity. 2. The composition of claim 1 wherein the cytolytic activity comprises NK characteristics. 3. The composition of claim 1 wherein the Th1/killer cells express granzyme B and perforin. 4. The composi... | A novel cell type has been generated that has both Th1 characteristics and cytolytic activity. These Th1/killer cells are CD4+ cells purified from peripheral blood and manipulated to have Th1 characteristics such as production of IFN-gamma combined with cytolytic activity similar to cytotoxic T-cells (CTL). The CTL act... | 1,600 |
1,048 | 1,048 | 14,406,957 | 1,627 | The present invention generally relates to the field of dietary therapies for treating disorders associated with mitochondrial dysfunction, including epilepsy. | 1. A composition suitable for human consumption comprising a decanoic acid and octanoic acid in a ratio of at least 2:1 wt/wt. 2. The composition according to claim 1 wherein the decanoic acid to octanoic acid ratio is at least 3:1 wt/wt. 3. The composition according to claim 1 wherein the decanoic acid to octanoic aci... | The present invention generally relates to the field of dietary therapies for treating disorders associated with mitochondrial dysfunction, including epilepsy.1. A composition suitable for human consumption comprising a decanoic acid and octanoic acid in a ratio of at least 2:1 wt/wt. 2. The composition according to cl... | 1,600 |
1,049 | 1,049 | 15,801,725 | 1,631 | Embodiments of the present invention are directed to a computer-implemented method for positive OTU identification. A non-limiting example of the computer-implemented method includes receiving, by a processor, a plurality of sequencing reads for a metagenome sample and, for each of the plurality of sequencing reads, a ... | 1. A computer-implemented method for positive operational taxonomic unit (OTU) identification, the method comprising:
receiving, by a processor, a plurality of sequencing reads for a metagenome sample and, for each of the plurality of sequencing reads, a corresponding OTU set comprising a plurality of OTUs; determining... | Embodiments of the present invention are directed to a computer-implemented method for positive OTU identification. A non-limiting example of the computer-implemented method includes receiving, by a processor, a plurality of sequencing reads for a metagenome sample and, for each of the plurality of sequencing reads, a ... | 1,600 |
1,050 | 1,050 | 13,981,789 | 1,619 | A simple cellulose sulphate based microencapsulation technology has been applied to encapsulate bacterial or other microbial cells, which produce and release digestive enzymes and thereby provides an acid resistant shelter for these microbial cells. Surprisingly, the resulting spheres were found to provide sufficient p... | 1. Encapsulated microbial cells, wherein the microbial cells are encapsulated in a microcapsule having a porous capsule wall, wherein the porous capsule wall comprises a complex formed from sodium cellulose sulphate and poly[dimethyldiallyl-ammonium chloride], and wherein the microcapsule protects the microbial cells f... | A simple cellulose sulphate based microencapsulation technology has been applied to encapsulate bacterial or other microbial cells, which produce and release digestive enzymes and thereby provides an acid resistant shelter for these microbial cells. Surprisingly, the resulting spheres were found to provide sufficient p... | 1,600 |
1,051 | 1,051 | 15,500,418 | 1,634 | The present invention relates to a method for selecting a target region of interest (ROI) in a target nucleic acid molecule using a nucleic acid probe comprising a 3′ sequence capable of hybridising to a target nucleic acid molecule and acting as a primer for the production of a complement of the target ROI (i.e. by ta... | 1. A method of selecting a target region of interest (ROI) in a target nucleic acid molecule, said ROI being flanked by a 3′ flanking sequence and a 5′ flanking sequence in the target molecule, said method comprising:
(a) providing a probe comprising
(i) a first target-binding site at a 3′ end region of said probe, whi... | The present invention relates to a method for selecting a target region of interest (ROI) in a target nucleic acid molecule using a nucleic acid probe comprising a 3′ sequence capable of hybridising to a target nucleic acid molecule and acting as a primer for the production of a complement of the target ROI (i.e. by ta... | 1,600 |
1,052 | 1,052 | 16,064,302 | 1,612 | The present invention relates to a microstructure including a biocompatible polymer or an adhesive and to a method for manufacturing the same. The present inventors optimized the aspect ratio according to the type of each microstructure, thereby ensuring the optimal tip angle and the diameter range for skin penetration... | 1. A microstructure comprising a biocompatible polymer or an adhesive, wherein the aspect ratio (w:h), configured of the diameter (w) of the bottom surface of the microstructure and the height (h) of the microstructure, is 1:5 to 1:1.5, and the angle of a distal tip is 10° to 40°. 2. The microstructure of claim 1, wher... | The present invention relates to a microstructure including a biocompatible polymer or an adhesive and to a method for manufacturing the same. The present inventors optimized the aspect ratio according to the type of each microstructure, thereby ensuring the optimal tip angle and the diameter range for skin penetration... | 1,600 |
1,053 | 1,053 | 14,651,887 | 1,657 | The present invention describes a composition comprising a mixture of human foetal keratinocyte cells and human foetal fibroblast cells, the ratio between said keratinocyte and fibroblast cells ranging from 0.75 to 2.5, preferably being 1:1 or 7:3. This composition is advantageously included in a bandage, said bandage ... | 1. A composition comprising a mixture of foetal human keratinocyte cells and foetal human fibroblastic cells, the ratio between said keratinocyte and fibroblast cells ranging from 0.75 to 2.5. 2. The composition according to claim 1, wherein said ratio is 1:1 or 7:3. 3. The composition according to claim 1 or 2, wherei... | The present invention describes a composition comprising a mixture of human foetal keratinocyte cells and human foetal fibroblast cells, the ratio between said keratinocyte and fibroblast cells ranging from 0.75 to 2.5, preferably being 1:1 or 7:3. This composition is advantageously included in a bandage, said bandage ... | 1,600 |
1,054 | 1,054 | 15,541,822 | 1,618 | The invention relates generally to a formulation in which metal tungstate or metal molybdate particles are encapsulated within biocompatible, diseased cell-targeting polymeric coatings. Such formulations render metal tungstate or metal molybdate particles suitable for in vivo biomedical imaging and therapeutic applicat... | 1. A formulation, comprising a crystalline particle or particle aggregate encapsulated within a biocompatible polymeric coating material, wherein the crystalline particle or particle aggregate is a metal tungstate material, a metal molybdate material, or a combination thereof. 2. The formulation of claim 1, wherein sai... | The invention relates generally to a formulation in which metal tungstate or metal molybdate particles are encapsulated within biocompatible, diseased cell-targeting polymeric coatings. Such formulations render metal tungstate or metal molybdate particles suitable for in vivo biomedical imaging and therapeutic applicat... | 1,600 |
1,055 | 1,055 | 14,240,825 | 1,616 | The present invention relates to a composition comprising a plant growth regulator and/or fungicide and/or insecticide and/or acaricide and the preparation process thereof. Additionally, the present invention discloses the use of a plant growth regulator and/or fungicide and/or insecticide and/or acaricide to prepare a... | 1. A composition, comprising:
a plant growth regulator and a fungicide; or a plant growth regulator and an insecticide; or a plant growth regulator and an acaricide; or a plant growth regulator and a fungicide and an insecticide; or a plant growth regulator and an insecticide and an acaricide; or a plant growth regulat... | The present invention relates to a composition comprising a plant growth regulator and/or fungicide and/or insecticide and/or acaricide and the preparation process thereof. Additionally, the present invention discloses the use of a plant growth regulator and/or fungicide and/or insecticide and/or acaricide to prepare a... | 1,600 |
1,056 | 1,056 | 16,202,198 | 1,619 | Methods of treating skin in need of treatment with retinoids are provided, which comprise cleansing the skin with a cleansing composition comprising a low irritation polymeric cleansing agent prior to treating with a retinoid. This improves the activity of the retinoid for treating for example signs of skin aging, acne... | 1. A method for treating skin, comprising in sequence:
(a) cleansing skin in need of treatment for signs of skin aging, acne, or rosacea with a cleansing composition comprising a low molecular weight hydrophobically modified polymer; and (b) topically applying to the skin a leave-on composition comprising a retinoid. 2... | Methods of treating skin in need of treatment with retinoids are provided, which comprise cleansing the skin with a cleansing composition comprising a low irritation polymeric cleansing agent prior to treating with a retinoid. This improves the activity of the retinoid for treating for example signs of skin aging, acne... | 1,600 |
1,057 | 1,057 | 14,772,437 | 1,653 | A device for testing the cleanliness of a cannula of a medical instrument can include a flexible guiding member having a first end, a second end, and an outer diameter, and a length extending from the first end to the second end, wherein the first end can be rounded and the length of the guiding member can be free of a... | 1. A device for testing the cleanliness of a cannula of a medical instrument comprising:
a flexible guiding member having a first end, a second end, an outer diameter, and a length extending from the first end to the second end, wherein the first end is rounded and the length of the guiding member is free of any cleani... | A device for testing the cleanliness of a cannula of a medical instrument can include a flexible guiding member having a first end, a second end, and an outer diameter, and a length extending from the first end to the second end, wherein the first end can be rounded and the length of the guiding member can be free of a... | 1,600 |
1,058 | 1,058 | 15,116,895 | 1,617 | Compositions comprise an amount of cinnamaldehyde that is orally tolerable, thus avoiding an unpleasant mouth feeling, and also tolerable in the gastrointestinal tract. The amount of cinnamaldehyde is supplemented by zinc, and the combination is effective to increase at least one of energy expenditure, sympathetic nerv... | 1. A method for weight maintenance comprising administering to an individual in need thereof a composition comprising cinnamaldehyde and zinc. 2. The method of claim 1 wherein the cinnamaldehyde is present in the composition in an amount that is safe and tolerable to ingest and, in combination with the zinc, effective ... | Compositions comprise an amount of cinnamaldehyde that is orally tolerable, thus avoiding an unpleasant mouth feeling, and also tolerable in the gastrointestinal tract. The amount of cinnamaldehyde is supplemented by zinc, and the combination is effective to increase at least one of energy expenditure, sympathetic nerv... | 1,600 |
1,059 | 1,059 | 16,587,818 | 1,613 | The embodiments described herein include methods and formulations for treating anaphylaxis and related acute allergic reactions. The methods and formulations include, but are not limited to, methods and formulations for delivering effective concentrations of levocetirizine and montelukast to a patient in need. The meth... | 1. A method of reducing the duration of anaphylaxis in a patient in need thereof, comprising administering to the patient an effective amount of a combination of levocetirizine and montelukast; wherein the combination is administered at the onset of symptoms. 2. The method of claim 1, wherein the combination is adminis... | The embodiments described herein include methods and formulations for treating anaphylaxis and related acute allergic reactions. The methods and formulations include, but are not limited to, methods and formulations for delivering effective concentrations of levocetirizine and montelukast to a patient in need. The meth... | 1,600 |
1,060 | 1,060 | 15,392,899 | 1,619 | Provided are compositions suitable for lifting or altering the color of keratinous substrates comprising: (a) at least one alkalizing agent; (b) at least two fatty substances; (c) at least one surfactant; (d) at least one cationic polymer; (e) at least one thickening agent: and (f) at least one solvent. The composition... | 1. A hair cosmetic composition for lifting or altering the color of keratinous substrates comprising:
a. at least one alkalizing agent selected from alkali metal carbonates, alkali metal phosphates, organic amines, hydroxide base compounds, and mixtures thereof; b. at least two fatty substances selected from alkanes co... | Provided are compositions suitable for lifting or altering the color of keratinous substrates comprising: (a) at least one alkalizing agent; (b) at least two fatty substances; (c) at least one surfactant; (d) at least one cationic polymer; (e) at least one thickening agent: and (f) at least one solvent. The composition... | 1,600 |
1,061 | 1,061 | 16,254,850 | 1,619 | The invention relates to the use of penflufen for protecting wood and wood-comprising materials against wood-destroying basidiomycetes. | 1. A process for protecting wood and wood-comprising materials against attack or destruction by wood-destroying basidiomycetes, the process comprising treating wood or wood-comprising material with a biocide composition comprising biocides, the biocides comprising:
at least one of penflufen and salts thereof; and at le... | The invention relates to the use of penflufen for protecting wood and wood-comprising materials against wood-destroying basidiomycetes.1. A process for protecting wood and wood-comprising materials against attack or destruction by wood-destroying basidiomycetes, the process comprising treating wood or wood-comprising m... | 1,600 |
1,062 | 1,062 | 15,326,531 | 1,611 | The present invention relates to a pediatric chewable tablet comprising a therapeutically effective amount of an anti-viral agent or pharmaceutical acceptable salt or derivative thereof, in particular Valaciclovir in complex with an ion exchange resin in a specific ratio in order to obtain a palatable and child-friendl... | 1. A chewable tablet comprising Valaciclovir or pharmaceutical acceptable salt or derivative thereof in complex with an ion exchange resin, wherein the ratio of Valaciclovir to the ion exchange resin is 1:0.8. 2. The chewable tablet according to claim 1, wherein the ion exchange resin is a cationic acid ion exchange re... | The present invention relates to a pediatric chewable tablet comprising a therapeutically effective amount of an anti-viral agent or pharmaceutical acceptable salt or derivative thereof, in particular Valaciclovir in complex with an ion exchange resin in a specific ratio in order to obtain a palatable and child-friendl... | 1,600 |
1,063 | 1,063 | 15,838,679 | 1,612 | Described herein are oral care compositions, comprising a peroxydone complex, a dispersant, and a polyvinylpyrrolidone copolymer structure-building agent. | 1. An oral care composition, comprising:
from about 0.01% to about 60% of peroxydone complex, based on a total weight of the oral care composition; from about 0.01% to about 990% of a non-aqueous dispersant, based on the total weight of the oral care composition, and from about 0.01% to about 60% of a polyvinylpyrrolid... | Described herein are oral care compositions, comprising a peroxydone complex, a dispersant, and a polyvinylpyrrolidone copolymer structure-building agent.1. An oral care composition, comprising:
from about 0.01% to about 60% of peroxydone complex, based on a total weight of the oral care composition; from about 0.01% t... | 1,600 |
1,064 | 1,064 | 16,364,121 | 1,629 | Disclosed herein are methods for treating conditions and/or disorders related to hyperglycemia. In particular, the present invention relates to methods of using (R)-(+)-verapamil or a pharmaceutically acceptable salt thereof and insulin or an insulin analogue in the treatment of mellitus and/or disorders related to dia... | 1. A method of treating a subject having diabetes mellitus and/or disorders related to diabetes mellitus comprising administering to the subject an effective amount of (R)-(+)-verapamil or a pharmaceutically acceptable salt thereof, and insulin or an insulin analogue. 2. The method of claim 1, wherein the insulin analo... | Disclosed herein are methods for treating conditions and/or disorders related to hyperglycemia. In particular, the present invention relates to methods of using (R)-(+)-verapamil or a pharmaceutically acceptable salt thereof and insulin or an insulin analogue in the treatment of mellitus and/or disorders related to dia... | 1,600 |
1,065 | 1,065 | 15,221,143 | 1,634 | A biomolecule analysis kit includes a reaction container configured to perform an enzymatic reaction, the reaction container including a base portion which has a container-shaped portion and a low-adsorption structural portion which is provided on at least the inner surface of the container-shaped portion, the low-adso... | 1. A biomolecule analysis kit comprising:
a reaction container configured to perform an enzymatic reaction, the reaction container including: a base portion which has a container-shaped portion, and a low-adsorption structural portion which is provided on at least the inner surface of the container-shaped portion, the ... | A biomolecule analysis kit includes a reaction container configured to perform an enzymatic reaction, the reaction container including a base portion which has a container-shaped portion and a low-adsorption structural portion which is provided on at least the inner surface of the container-shaped portion, the low-adso... | 1,600 |
1,066 | 1,066 | 14,512,369 | 1,639 | The invention provides methods, apparatuses, and compositions for high-throughput amplification sequencing of specific target sequences in one or more samples. In some aspects, barcode-tagged polynucleotides are sequenced simultaneously and sample sources are identified on the basis of barcode sequences. In some aspect... | 1-60. (canceled) 61. A method of detecting genetic variation in a subject's genome comprising:
(a) providing a plurality of clusters of polynucleotides, wherein (i) each cluster comprises multiple copies of a nucleic acid duplex attached to a support; (ii) each duplex in a cluster comprises a first molecule comprising ... | The invention provides methods, apparatuses, and compositions for high-throughput amplification sequencing of specific target sequences in one or more samples. In some aspects, barcode-tagged polynucleotides are sequenced simultaneously and sample sources are identified on the basis of barcode sequences. In some aspect... | 1,600 |
1,067 | 1,067 | 15,326,767 | 1,617 | The present invention relates to water dispersible mini-tablets of Enalapril or a pharmaceutically acceptable salt thereof for use in the treatment of hypertension in a pediatric formulation. The pediatric formulation is defined as 0 to 18 years of age. The present invention also provides a method of manufacturing of s... | 1. A water dispersible minitablet comprising Enalapril or pharmaceutically acceptable salts thereof and one or more pharmaceutically acceptable excipients selected from a disintegrant, a diluent, a lubricant and a glidant, wherein the minitablet is capable of dispersing in water in a period of less than 15 seconds, in ... | The present invention relates to water dispersible mini-tablets of Enalapril or a pharmaceutically acceptable salt thereof for use in the treatment of hypertension in a pediatric formulation. The pediatric formulation is defined as 0 to 18 years of age. The present invention also provides a method of manufacturing of s... | 1,600 |
1,068 | 1,068 | 15,529,656 | 1,612 | An oral care mouth rinse composition containing at least one ionic tin source and polyvinylpyrrolidone wherein the polyvinylpyrrolidone is present in an amount of from 1.5 to 4 weight % based on the total weight of the oral care mouth rinse composition is provided. | 1. An oral care mouth rinse composition comprising
(i) at least one source of ionic tin and (ii) polyvinylpyrrolidone
wherein the polyvinylpyrrolidone is present in an amount of from 1.5 to 4 weight %, based on the total weight of the oral care mouth rinse composition. 2. The oral care mouth rinse composition accordin... | An oral care mouth rinse composition containing at least one ionic tin source and polyvinylpyrrolidone wherein the polyvinylpyrrolidone is present in an amount of from 1.5 to 4 weight % based on the total weight of the oral care mouth rinse composition is provided.1. An oral care mouth rinse composition comprising
(i) ... | 1,600 |
1,069 | 1,069 | 15,174,540 | 1,653 | Methods and materials for treating bacterial vaginosis (“BV”) are provided. Cervicovaginal secretions (“CVS”) from a woman with vaginal microbiota dominated (>50%) by one of the species of lactobacillus typically found in the human vagina, e.g. Lactobacillus crispatus, L. iners, L. gasseri, L jensenii , is transplan... | 1. An isolated cervicovaginal secretion comprising vaginal microbiota, wherein at least 50% of the vaginal microbiota is one species typically found in the human vagina, e.g. Lactobacillus crispatus, Lactobacillus iners, Lactobacillus gasseri, or Lactobacillus jensenii, having no evidence of sexually transmitted diseas... | Methods and materials for treating bacterial vaginosis (“BV”) are provided. Cervicovaginal secretions (“CVS”) from a woman with vaginal microbiota dominated (>50%) by one of the species of lactobacillus typically found in the human vagina, e.g. Lactobacillus crispatus, L. iners, L. gasseri, L jensenii , is transplan... | 1,600 |
1,070 | 1,070 | 15,236,807 | 1,654 | A bone gel composition consists of cortical bone. The cortical bone is made from cut pieces freeze-dried then ground into particles and demineralized then freeze-dried. A volume of the particles is placed in a solution of sterile water to create a mixture, the water volume being at least twice the particle volume, the ... | 1. A bone gel composition consisting of cortical bone consists of cortical bone made from cut pieces freeze dried then ground into particles and demineralized then freeze-dried, wherein a volume of the particles is placed in a solution of sterile water to create a mixture, the water volume being at least twice the volu... | A bone gel composition consists of cortical bone. The cortical bone is made from cut pieces freeze-dried then ground into particles and demineralized then freeze-dried. A volume of the particles is placed in a solution of sterile water to create a mixture, the water volume being at least twice the particle volume, the ... | 1,600 |
1,071 | 1,071 | 16,687,447 | 1,623 | Administration of low molecular weight (10,000-20,000 Daltons, or lower) pectins, particularly modified citrus pectins (MCP), like PectaSol-C reduces galectins-3 levels in vivo. Reduction of galectin-3 levels by MCP inhibits inflammation, inhibits fibrosis formation in organs and tissues, and inhibits cancer formation,... | 1-6. (canceled) 7. A method of treating a mammal which benefits from a reduction in available circulating galectin-3, comprising the steps of:
a) Identifying a mammal in need of treatment for kidney damage, and b) Administering to said mammal an amount of modified pectin of molecular weight of 3,000-13,000 Daltons, in ... | Administration of low molecular weight (10,000-20,000 Daltons, or lower) pectins, particularly modified citrus pectins (MCP), like PectaSol-C reduces galectins-3 levels in vivo. Reduction of galectin-3 levels by MCP inhibits inflammation, inhibits fibrosis formation in organs and tissues, and inhibits cancer formation,... | 1,600 |
1,072 | 1,072 | 13,824,548 | 1,619 | The present invention relates to a cosmetic composition comprising, in a physiologically acceptable medium, at least water, at least alkylcellulose, at least a first nonvolatile oil chosen from silicone oils and/or fluoro oils, and at least a second hydrocarbon-based nonvolatile oil chosen from C10-C26 alcohols, prefer... | 1-18. (canceled) 19. A cosmetic composition comprising, in a physiologically acceptable medium:
at least 5% by weight of water; at least alkylcellulose, the alkyl residue of which comprises between 1 and 6 carbon atoms; at least a first nonvolatile oil chosen from silicone oils and/or fluoro oils; and at least a second... | The present invention relates to a cosmetic composition comprising, in a physiologically acceptable medium, at least water, at least alkylcellulose, at least a first nonvolatile oil chosen from silicone oils and/or fluoro oils, and at least a second hydrocarbon-based nonvolatile oil chosen from C10-C26 alcohols, prefer... | 1,600 |
1,073 | 1,073 | 15,706,177 | 1,655 | A composition useful for promoting a desired oral microbiota to treat an allergy related respiratory condition in a subject in need of such treatment, the composition including an amino acid containing ingredient including individual molecules of L-arginine; the composition in a configuration to be maintained within th... | 1. A composition useful for promoting a desired oral microbiota to treat an allergy related respiratory condition in a subject in need of such treatment comprising:
an amino acid containing ingredient comprising individual molecules of L-arginine; the composition in a configuration to be maintained within the oral cavi... | A composition useful for promoting a desired oral microbiota to treat an allergy related respiratory condition in a subject in need of such treatment, the composition including an amino acid containing ingredient including individual molecules of L-arginine; the composition in a configuration to be maintained within th... | 1,600 |
1,074 | 1,074 | 15,630,465 | 1,612 | This invention relates to oral care compositions comprising a first source of zinc which is zinc citrate, a second source of zinc which is zinc oxide or zinc lactate, a stannous ion source, and a polyphosphate, as well as to methods of using and of making these compositions. | 1. An oral care composition comprising:
a. A first source of zinc comprising zinc oxide; b. A second source of zinc comprising zinc citrate or zinc lactate; and c. stannous ion source. 2. The oral care composition of claim 1, wherein the first zinc source is zinc oxide and the second zinc source is zinc citrate. 3. The... | This invention relates to oral care compositions comprising a first source of zinc which is zinc citrate, a second source of zinc which is zinc oxide or zinc lactate, a stannous ion source, and a polyphosphate, as well as to methods of using and of making these compositions.1. An oral care composition comprising:
a. A ... | 1,600 |
1,075 | 1,075 | 15,520,795 | 1,651 | A tissue sample processing system and associated methods is disclosed and described. The tissue sample processing system ( 100 ) can include a microfluidic separating system ( 110 ). The microfluidic separating system ( 110 ) can include a fluid channel to receive a carrier fluid ( 104 ) and a tissue sample ( 102 ), an... | 1. A method of separating sperm cells, comprising:
obtaining a microfluidic separating system having a fluid channel and a plurality of outlets; and disposing a sperm sample in the fluid channel, wherein flow of the sperm sample in the fluid channel facilitates segregation of materials in the sperm sample based on size... | A tissue sample processing system and associated methods is disclosed and described. The tissue sample processing system ( 100 ) can include a microfluidic separating system ( 110 ). The microfluidic separating system ( 110 ) can include a fluid channel to receive a carrier fluid ( 104 ) and a tissue sample ( 102 ), an... | 1,600 |
1,076 | 1,076 | 14,639,162 | 1,633 | A therapeutic patch includes at least one layer of a nanofiber fabric and at least one of a plurality of stem cells or a plurality of stem cell-derived paracrine factors embedded in the nanofiber fabric. The therapeutic patch is produced such that the nanofiber fabric is formed of a nanofiber web. | 1. A therapeutic patch, comprising:
at least one layer of a nanofiber fabric; and at least one of a plurality of stem cells and a plurality of stem cell-derived paracrine factors embedded in the nanofiber fabric,
wherein the nanofiber fabric comprises a nanofiber web. 2. The therapeutic patch according to claim 1, whe... | A therapeutic patch includes at least one layer of a nanofiber fabric and at least one of a plurality of stem cells or a plurality of stem cell-derived paracrine factors embedded in the nanofiber fabric. The therapeutic patch is produced such that the nanofiber fabric is formed of a nanofiber web.1. A therapeutic patch... | 1,600 |
1,077 | 1,077 | 15,189,839 | 1,656 | The present invention provides a method of modulating various aspects of the immune system. In particular, the present invention teaches the use of diketopiperazines (DKPs) to modulate various aspects of the immune system such as, for example, inflammation, T-cells and various cytokines. | 1. A method of inhibiting inflammation, the method comprising administering to an individual in need thereof an effective amount of a pharmaceutical composition comprising a low molecular weight fraction (LMWF) of human serum albumin (HSA), wherein the individual is not administered a cyclooxygenase-2 (COX-2) antagonis... | The present invention provides a method of modulating various aspects of the immune system. In particular, the present invention teaches the use of diketopiperazines (DKPs) to modulate various aspects of the immune system such as, for example, inflammation, T-cells and various cytokines.1. A method of inhibiting inflam... | 1,600 |
1,078 | 1,078 | 15,322,003 | 1,649 | The present invention provides a composition for treating ischemic diseases or neuroinflammatory diseases. PSA-NCAM-positive neural progenitor cells used in the present invention promote angiogenesis in injected tissue and inhibit an inflammatory response. The PSA-NCAM-positive neural progenitor cells can be simply iso... | 1-18. (canceled) 19. A method for treating ischemic disease or neuroinflammatory disease, the method comprising administering a composition containing poly-sialylated neural cell adhesion molecule (PSA-NCAM)-positive neural precursor cells as an active ingredient to a subject in need thereof. 20. A method for treating ... | The present invention provides a composition for treating ischemic diseases or neuroinflammatory diseases. PSA-NCAM-positive neural progenitor cells used in the present invention promote angiogenesis in injected tissue and inhibit an inflammatory response. The PSA-NCAM-positive neural progenitor cells can be simply iso... | 1,600 |
1,079 | 1,079 | 15,840,046 | 1,612 | A two-phase oral care whitening composition including a hydrophobic phase and a hydrophilic phase, and methods for oral care whitening teeth with the same are provided. The hydrophobic phase may include a source of hydrogen peroxide and an acyl donor. The hydrophilic phase may include an enzyme that catalyzes the gener... | 1. A two-phase oral care whitening composition, comprising:
a hydrophobic phase comprising a source of hydrogen peroxide and an acyl donor; and a hydrophilic phase comprising an enzyme that catalyzes the generation of peracetic acid between the source of hydrogen peroxide and the acyl donor, wherein at least one of the... | A two-phase oral care whitening composition including a hydrophobic phase and a hydrophilic phase, and methods for oral care whitening teeth with the same are provided. The hydrophobic phase may include a source of hydrogen peroxide and an acyl donor. The hydrophilic phase may include an enzyme that catalyzes the gener... | 1,600 |
1,080 | 1,080 | 16,384,782 | 1,632 | The present invention relates to processes for transfecting cells. In particular, the present invention relates to processes for using CRISPR to incorporate a polynucleotide into the genome of an avian primordial germ cell (PGC). | 1. (canceled) 2. A process for using CRISPR to incorporate a polynucleotide into the genome of an avian primordial germ cell (PGC), comprising:
(i) injecting, into a blood vessel of an avian embryo at stage 13-17 that is contained in an egg, a transfection mixture comprising:
(a) a DNA polynucleotide encoding a Type II... | The present invention relates to processes for transfecting cells. In particular, the present invention relates to processes for using CRISPR to incorporate a polynucleotide into the genome of an avian primordial germ cell (PGC).1. (canceled) 2. A process for using CRISPR to incorporate a polynucleotide into the genome... | 1,600 |
1,081 | 1,081 | 15,195,748 | 1,633 | The invention disclosed herein provides systems and methods designed to facilitate human limbal stem/progenitor cell culture including a novel 3-dimensional (3D) sandwich method/system in which human limbal stem/progenitor cells and feeder cells are separately cultured on opposite sides of a porous membrane. | 1. A method of maintaining human limbal stem cells of the corneal epithelium in an undifferentiated human limbal stem cell phenotype, wherein the phenotype is characterized by a small, uniform and compact cellular morpology, the method comprising culturing the human limbal stem cell cells in the system comprising:
a co... | The invention disclosed herein provides systems and methods designed to facilitate human limbal stem/progenitor cell culture including a novel 3-dimensional (3D) sandwich method/system in which human limbal stem/progenitor cells and feeder cells are separately cultured on opposite sides of a porous membrane.1. A method... | 1,600 |
1,082 | 1,082 | 15,537,121 | 1,634 | The present invention provides an oligonucleotide probe for single nucleotide polymorphism detection to be used for a target nucleic acid where a single nucleotide polymorphism is present, the oligonucleotide probe comprising a reporter region, an anchor region, and a linker region. The reporter region comprises: an ol... | 1. An oligonucleotide probe for single nucleotide polymorphism detection to be used for a target nucleic acid where a single nucleotide polymorphism is present, wherein
the target nucleic acid comprises a first target sequence corresponding to a region comprising the single nucleotide polymorphism, and a second target ... | The present invention provides an oligonucleotide probe for single nucleotide polymorphism detection to be used for a target nucleic acid where a single nucleotide polymorphism is present, the oligonucleotide probe comprising a reporter region, an anchor region, and a linker region. The reporter region comprises: an ol... | 1,600 |
1,083 | 1,083 | 15,788,255 | 1,612 | Oral care compositions comprising an antifibrinolytic agent (e.g., tranexamic acid) and stannous ion source are provided for promoting Gum Health of a consumer. | 1. An oral care composition comprising:
a) from 0.01% to 5%, by weight of the composition, of a stannous ion source; and b) from 0.01% to 10%, by weight of the composition, of an antifibrinolytic agent. 2. The oral care composition according to claim 1, wherein the antifibrinolytic agent is a compound of formula (I):
... | Oral care compositions comprising an antifibrinolytic agent (e.g., tranexamic acid) and stannous ion source are provided for promoting Gum Health of a consumer.1. An oral care composition comprising:
a) from 0.01% to 5%, by weight of the composition, of a stannous ion source; and b) from 0.01% to 10%, by weight of the ... | 1,600 |
1,084 | 1,084 | 15,973,243 | 1,637 | Digital assay system, including methods, apparatus, and compositions, for assay of one or more targets in a set of partitions containing a generic reporter of target amplification. | 1. A method of performing a digital assay, the method comprising:
forming partitions each including a portion of a same mixture, the mixture containing a target and also containing a generic reporter that is sensitive to amplification of the target, wherein only a subset of the partitions each contain at least one copy... | Digital assay system, including methods, apparatus, and compositions, for assay of one or more targets in a set of partitions containing a generic reporter of target amplification.1. A method of performing a digital assay, the method comprising:
forming partitions each including a portion of a same mixture, the mixture... | 1,600 |
1,085 | 1,085 | 15,553,638 | 1,622 | Described are also corresponding pharmaceutical formulations, cosmetic preparations and preparations for pleasure and/or nutrition, suitable for consumption, as well as methods for producing CBDV and THCV. | 1. A mixture comprising one or more compounds of formula (A) and/or one or more of their salts
wherein R1 is an aliphatic rest with none or one, two, three or more than three hydroxyl groups, wherein the total number of C-atoms in the aliphatic rest R1 is not bigger than 15,
an wherein the aliphatic rest is
s... | Described are also corresponding pharmaceutical formulations, cosmetic preparations and preparations for pleasure and/or nutrition, suitable for consumption, as well as methods for producing CBDV and THCV.1. A mixture comprising one or more compounds of formula (A) and/or one or more of their salts
wherein R1... | 1,600 |
1,086 | 1,086 | 13,675,306 | 1,615 | An improved method for diagnosing and characterizing peripheral nerve lesions to permit early identification and characterization of peripheral nerve injuries that will require surgical intervention. | 1. A method to diagnose and characterize peripheral nerve lesions, the method including the step of:
introducing a chemical agent operable to bind directly to a peripheral nerve lesion in which the blood-nerve barrier is compromised, wherein the chemical agent does not interact with a target molecule unless the blood-n... | An improved method for diagnosing and characterizing peripheral nerve lesions to permit early identification and characterization of peripheral nerve injuries that will require surgical intervention.1. A method to diagnose and characterize peripheral nerve lesions, the method including the step of:
introducing a chemic... | 1,600 |
1,087 | 1,087 | 15,968,364 | 1,611 | An avermectin-based topical formulation is disclosed which is useful for prevention and treatment of head lice (Pediculus humanus capitis). This topical formulation may be formulated as a shampoo-condition which comprises an effective amount of avermectin, solubilizers, suspending agents, preservatives, nonionic surfac... | 1.-20. (canceled) 21. A method for treatment or prophylaxis of a lice infestation, the method comprising:
(a) applying a pediculicidal formulation to a human scalp infested with lice; wherein the pediculicidal formulation comprises:
about 0.1% to about 2.0% by weight ivermectin;
less than about 30% of a pharmaceuticall... | An avermectin-based topical formulation is disclosed which is useful for prevention and treatment of head lice (Pediculus humanus capitis). This topical formulation may be formulated as a shampoo-condition which comprises an effective amount of avermectin, solubilizers, suspending agents, preservatives, nonionic surfac... | 1,600 |
1,088 | 1,088 | 15,103,208 | 1,617 | Compositions comprising a substrate coated with a sulfonylurea herbicide, and methods for making and using such compositions, are generally described herein. | 1. A composition comprising a substrate, a sulfonylurea herbicide and a carrier. 2. The composition of claim 1, wherein the carrier comprises polybutene, white mineral oil, mineral seal oil, hexylene glycol, or combinations thereof. 3. The composition of claim 1 or 2, wherein the carrier comprises 0.01-10.00% by weight... | Compositions comprising a substrate coated with a sulfonylurea herbicide, and methods for making and using such compositions, are generally described herein.1. A composition comprising a substrate, a sulfonylurea herbicide and a carrier. 2. The composition of claim 1, wherein the carrier comprises polybutene, white min... | 1,600 |
1,089 | 1,089 | 15,538,691 | 1,641 | The present invention generally relates to method for forming an immunolabeling complex, the immunolabeling complex comprising a labeled monovalent biotin-binding composition. The invention also related to the use of the antibody-reporter molecule complex for detecting a target in a sample. | 1. A method for forming an immunolabeling complex, wherein the method comprises:
selecting a first biotinylated primary antibody; selecting a first monovalent biotin-binding composition labeled with a first reporter element, and mixing, in a reaction vessel, the first biotinylated primary antibody with the first labele... | The present invention generally relates to method for forming an immunolabeling complex, the immunolabeling complex comprising a labeled monovalent biotin-binding composition. The invention also related to the use of the antibody-reporter molecule complex for detecting a target in a sample.1. A method for forming an im... | 1,600 |
1,090 | 1,090 | 16,100,158 | 1,633 | Methods for introducing exogenous material into a cell are provided, which include exposing the cell to a transient decrease in pressure in the presence of the exogenous material. Also provided are devices for performing the method of the invention. | 1. A method introducing an exogenous material into the cell, comprising:
inducing a first condition around the cell where there is an ambient pressure insufficient to lyse the cell; inducing a second condition around the cell where the second pressure is less than the ambient pressure; and inducing a third condition ar... | Methods for introducing exogenous material into a cell are provided, which include exposing the cell to a transient decrease in pressure in the presence of the exogenous material. Also provided are devices for performing the method of the invention.1. A method introducing an exogenous material into the cell, comprising... | 1,600 |
1,091 | 1,091 | 15,245,426 | 1,641 | The present invention relates to a method for detecting a target substance that is useful for detection of a glycoprotein and the like comprising a specific sugar chain, a reagent for detecting a target substance, a carrier and a method for manufacturing the carrier. | 1. A reagent for detecting a target substance comprising a sugar chain that binds with lectin of Wisteria floribunda (WFA),
wherein the reagent comprises a dimeric WFA immobilized carrier comprising a solid phase carrier and a dimeric WFA, and the dimeric WFA is immobilized on the solid phase carrier. 2. The reagent ac... | The present invention relates to a method for detecting a target substance that is useful for detection of a glycoprotein and the like comprising a specific sugar chain, a reagent for detecting a target substance, a carrier and a method for manufacturing the carrier.1. A reagent for detecting a target substance compris... | 1,600 |
1,092 | 1,092 | 15,442,695 | 1,636 | The invention provides methods of genetically engineering a C1-fixing bacterium using a Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated (Cas) (CRISPR/Cas) system. Preferably, the Cas protein is under the control of an inducible promoter. | 1. A method of genetically engineering a C1-fixing bacterium comprising introducing into a C1-fixing bacterium containing a DNA molecule comprising a target sequence an engineered, non-naturally occurring Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated (Cas) (CRISPR/Cas) system comp... | The invention provides methods of genetically engineering a C1-fixing bacterium using a Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated (Cas) (CRISPR/Cas) system. Preferably, the Cas protein is under the control of an inducible promoter.1. A method of genetically engineering a C1-fi... | 1,600 |
1,093 | 1,093 | 14,768,970 | 1,631 | A system including a device with at least one processor and memory storing computer-executable instructions that, when executed by the at least one processor, perform a method of identifying glycopeptides in a sample, the method including, analyzing a mass spectrum of the sample to identify at least one portion of the ... | 1. At least one computer-readable storage medium storing computer-executable instructions that, when executed by at least one processor, perform a method of identifying glycopeptides in a sample, the method comprising:
analyzing a mass spectrum of the sample to identify at least one portion of the mass spectrum having ... | A system including a device with at least one processor and memory storing computer-executable instructions that, when executed by the at least one processor, perform a method of identifying glycopeptides in a sample, the method including, analyzing a mass spectrum of the sample to identify at least one portion of the ... | 1,600 |
1,094 | 1,094 | 14,772,063 | 1,634 | Provided herein is a method for making a pool of probes by primer extension. In certain embodiments, the method comprises hybridizing a first population of oligonucleotides comprising a top strand sequence having the following formula V1-B-3′ with a second population of oligonucleotides comprising a bottom strand seque... | 1. A method comprising:
a) hybridizing a first population of oligonucleotides comprising a top strand sequence having the following formula:
V1-B-3′
with a second population of oligonucleotides comprising a bottom strand sequence having the following formula:
V2′-B′-3′
to provide a population of duplexes; wherein... | Provided herein is a method for making a pool of probes by primer extension. In certain embodiments, the method comprises hybridizing a first population of oligonucleotides comprising a top strand sequence having the following formula V1-B-3′ with a second population of oligonucleotides comprising a bottom strand seque... | 1,600 |
1,095 | 1,095 | 15,436,984 | 1,617 | The present invention is directed to novel insecticidal and/or miticidal compositions comprising bifenthrin and a cyano-pyrethroid. The compositions exhibit an unexpected increase in insecticidal activity as compared to the insecticidal activity of the individual components. | 1. A miticidal composition comprising bifenthrin and a cyano-pyrethroid selected from the group consisting of acrinathrin, cycloprothrin, tralomethrin, fenvalerate, beta-cyfluthrin, flucythrinate, beta-cypermethrin, theta-cypermethrin, cyphenothrin, cyhalothrin, fluvalinate and fenpropathrin. 2. A composition of claim ... | The present invention is directed to novel insecticidal and/or miticidal compositions comprising bifenthrin and a cyano-pyrethroid. The compositions exhibit an unexpected increase in insecticidal activity as compared to the insecticidal activity of the individual components.1. A miticidal composition comprising bifenth... | 1,600 |
1,096 | 1,096 | 15,697,765 | 1,629 | An aqueous solution includes a silver complex and a pH buffer. The silver complex may include a silver atom in complex with an organic acid compound, such as dihydrogen citrate. | 1. A biocide comprising:
an aqueous solution including a silver complex and a pH buffer. 2. The biocide as recited in claim 1, wherein the aqueous solution has a pH of 6-10, and a pH of 3 or less without the pH buffer. 3. The biocide as recited in claim 1, wherein the silver complex includes a silver atom in complex wi... | An aqueous solution includes a silver complex and a pH buffer. The silver complex may include a silver atom in complex with an organic acid compound, such as dihydrogen citrate.1. A biocide comprising:
an aqueous solution including a silver complex and a pH buffer. 2. The biocide as recited in claim 1, wherein the aque... | 1,600 |
1,097 | 1,097 | 14,654,650 | 1,618 | There is provided a microparticle composition suitable for molecular imaging, the composition comprising microparticles, wherein the microparticles comprise: a core microparticle structure having a central area and a shell, and wherein the core microparticle structure comprises (i) a phosphatidylcholine lipid: (ii) a p... | 1. A microparticle composition suitable for molecular imaging, the composition comprising microparticles, wherein the microparticles comprise: a core microparticle structure having a central area and a shell, and wherein the core microparticle structure comprises:
(i) a phosphatidylcholine lipid; (ii) a phosphatidyleth... | There is provided a microparticle composition suitable for molecular imaging, the composition comprising microparticles, wherein the microparticles comprise: a core microparticle structure having a central area and a shell, and wherein the core microparticle structure comprises (i) a phosphatidylcholine lipid: (ii) a p... | 1,600 |
1,098 | 1,098 | 15,238,357 | 1,612 | Programmable molecular imprinted polymers (MIPs) that have modified binding site kinetics for target imprintable entities (TIEs) that operate to control the adsorption, binding, release and equilibrium distribution of related materials into and out of the MIPs, which are useful for the controlled adsorption, controlled... | 1. A molecularly imprinted polymer system for use in the catch and release of multiple materials comprising:
(a) a first molecularly imprinted polymer with at least one first suboptimal average associative binding constant with respect to a first material to be released; (b) a second molecularly imprinted polymer with ... | Programmable molecular imprinted polymers (MIPs) that have modified binding site kinetics for target imprintable entities (TIEs) that operate to control the adsorption, binding, release and equilibrium distribution of related materials into and out of the MIPs, which are useful for the controlled adsorption, controlled... | 1,600 |
1,099 | 1,099 | 13,386,349 | 1,643 | A delivery vehicle, for delivering a pharmaceutically active agent or a marker to a cell, comprising a ligand binding portion specific for a Fas Ligand, and a carrier for the pharmaceutically active agent or marker. | 1. A delivery vehicle comprising a ligand binding portion specific for a Fas Ligand, and a carrier for a pharmaceutically active agent or marker. 2. A delivery vehicle as claimed in claim 1, wherein the carrier is a microparticle, nanoparticle, microcapsule, microsphere, micelle or liposome. 3-4. (canceled) 5. A delive... | A delivery vehicle, for delivering a pharmaceutically active agent or a marker to a cell, comprising a ligand binding portion specific for a Fas Ligand, and a carrier for the pharmaceutically active agent or marker.1. A delivery vehicle comprising a ligand binding portion specific for a Fas Ligand, and a carrier for a ... | 1,600 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.